  Background: Recently, the reaction $^{nat}$V($\alpha$,x)$^{52g}$Mn has been
proposed as a possible alternative to the standard $^{nat}$Cr($p$,x)$^{52g}$Mn
one, but improvements in the modeling were needed to better compare the two
production routes.
  Purpose: This work focuses on the development of precise simulations and
models to compare the $^{52g}$Mn production from both reactions in terms of
amount of activity and radionuclidic purity (RNP), as well as in terms of dose
increase (DI) due to the co-produced radioactive contaminants, with respect to
a pure $^{52g}$MnCl$_2$ injection.
  Methods: The nuclear code Talys has been employed to optimize the
$^{nat}$V($\alpha$,x)$^{52g}$Mn cross section by tuning the parameters of the
microscopic level densities. Dosimetric assessments of [$^{xx}$Mn]Cl$_2$ have
been accomplished with OLINDA software 2.2.0 using female and male phantoms. At
the end, the yield of $^{xx}$Mn radioisotopes estimated for the two production
routes have been combined with the dosimetric results, to assess the DI at
different times after the end of the irradiation.
  Results: Good agreement was obtained between cross sections calculations and
measurements. The comparison of the two reaction channels suggests that
$^{nat}$V($\alpha$,x)$^{52g}$Mn leads to higher yield and higher purity,
resulting in a less harmful impact on patients' health in terms of DI.
  Conclusions: Both $^{nat}$V($\alpha$,x) and $^{nat}$Cr($p$,x) production
routes provide clinically acceptable $^{52g}$MnCl$_2$ for PET imaging. However,
the $^{nat}$V($\alpha$,x)$^{52g}$Mn reaction provides a DI systematically lower
than the one obtainable with $^{nat}$Cr($p$,x)$^{52g}$Mn and a longer time
window in which it can be used clinically (RNP $\ge$ 99\%).
